Form 4: Gilead Sciences Executive Johanna Mercier Sells Shares Under 10b5-1 Trading Plan

Johanna Mercier, Chief Commercial Officer of Gilead Sciences, sold a portion of her holdings in common stock under a pre-arranged Rule 10b5-1 trading plan.

Summary

• On September 12, 2024, Johanna Mercier, the Chief Commercial Officer of Gilead Sciences, sold shares of the company's common stock.
• The sales were executed in two transactions at prices of $84.23 and $83.25 per share.
• A total of 15,925 shares were sold at $84.23 and 13,432 shares were sold at $83.25.
• These transactions were conducted under a pre-arranged Rule 10b5-1 trading plan adopted on April 30, 2024.
• Following the reported transactions, Mercier directly owns 78,127 shares of Gilead Sciences common stock.

Sentiment

Score: 5

Explanation: The document is a routine SEC filing regarding stock sales by an executive under a pre-arranged trading plan. It doesn't inherently convey positive or negative sentiment.

Industry Context

Executive stock sales are a common occurrence, and sales under 10b5-1 plans are generally viewed as less impactful since they are pre-planned and not based on current insider information.

Stakeholder Impact

• The stock sale may have a minor impact on shareholders due to the increased supply of shares in the market, but the effect is likely to be minimal given the pre-planned nature of the transaction.

Key Dates